Objectives: The objective of this prospective, open-label study was to determine the long-term effect of medicinal cannabis treatment on pain and functional outcomes in participants with treatmentresistant chronic pain.
C hronic pain is one of the leading causes of disability worldwide. With 15% to 30% prevalence in the general adult population 1, 2 and annual costs in the United States alone exceeding 500 billion dollars, 3 it has an enormous negative societal impact. Current pharmacotherapy of chronic pain is less than satisfactory, 4, 5 and less than two-thirds of the patients with chronic pain obtain sufficient pain relief with the available drugs. 6 Even with the use of biopsychosocial approach to chronic pain, long-term pain management outcomes are often suboptimal. 7, 8 Clearly, additional approaches are needed to improve treatment outcomes of patients with chronic pain.
Cannabis has been used for centuries in medicine for various indications, but a substantial progress in the biomedical research of exogenous and endogenous cannabinoids did not begin before the discovery of the chemical structure of D-9 tetrahydrocannabinol (THC) and additional cannabinoids in the 1960s. 9 The analgesic effect of cannabinoids has been demonstrated by extensive preclinical research, 10 but has been less consistent in human studies. [11] [12] [13] [14] [15] [16] [17] Since the publication of the initial systematic review and meta-analysis on the analgesic effect of cannabinoids 12 and a call for more extensive cannabinoid pain research, 13 more clinical evidence has become available in the last decade. 18, 19 Earlier studies demonstrated cannabinoid efficacy in pain and spasticity associated with multiple sclerosis (MS), 15, 17 but 2 recent trials of oromucosal THC/cannabidiol (THC/CBD) failed to show improved analgesia over placebo in neuropathic pain in MS and diabetic polyneuropathy. 14, 16 A few placebo-controlled studies have demonstrated the effectiveness of smoked cannabis in pain associated with HIV neuropathy 20, 21 and peripheral nerve injury, 22 but these were of very short, 5 to 14 days', duration. Long-term (beyond 15 wk) effectiveness data on oral and smoked cannabinoids in chronic pain are available only from small case series. 11, 23, 24 Overall, the available evidence indicates that smoked cannabis may be effective for chronic pain treatment, but there is a lack of long-term prospective data in a sufficiently large patient sample. 19 Medicinal cannabis is not FDA approved, but was recently approved by the Israeli Ministry of Health, including for the treatment of chronic pain. Given the lack of longitudinal data on the analgesic efficacy of cannabis, the objective of the current study was to prospectively assess the long-term effect of cannabis on pain and functional outcomes in patients with chronic pain. This was a prospective, open-label, single-arm longitudinal study carried out at the ambulatory pain clinic of  the Pain Relief Unit, Hadassah-Hebrew University Medical Center, in Jerusalem. The study was conducted and is reported in concordance with the STROBE statement. 25 Between June 1, 2010 and January 1, 2013, the study enrolled all consecutive patients who met the following inclusion criteria: (1) age above 18 years, (2) chronic pain with a duration of 3 months or longer, and (3) a lack of satisfactory analgesic response or intolerable adverse effects with at least 2 analgesics from 2 different drug classes at full dose.
PATIENTS AND METHODS
Participants were excluded if they (1) were unable to read and understand the intervention risks and benefits form, (2) had a history of drug abuse or dependence, (3) had a psychiatric comorbidity (or history) of schizophrenia or acute psychosis, or a family history of schizophrenia, (4) had a high risk of drug abuse (determined by the study psychologist) or nonadherence to pharmacotherapy (determined by the study clinical pharmacist), (5) did not have a proper trial with 2 first/second-line analgesic drugs for the underlying painful condition (ie, the dosage was increased to the maximum recommended dose, or doselimiting side effects appeared), or (6) were pregnant or breastfeeding.
For participants who fulfilled the above criteria, an individual application for cannabis treatment was sent for approval by the Ministry of Health. The application was submitted by a pain management physician so that an individual patient would receive a license to use medicinal cannabis for the treatment of chronic pain. In addition to confirmation that the patient was treated in the pain clinic, it included the patient's pain medical history, diagnosis, and a statement that the patient had exhausted conventional analgesic modalities for the relevant pain diagnosis as stipulated by the Ministry of Health. Only after such individual approval, a temporary license to use medicinal cannabis was issued, with a requirement for license renewal every 6 to 12 months. All participants read and signed the consent form on the potential risks and benefits of the intervention at the time of application to the Ministry of Health. The questionnaire used for data collection in this study was approved separately by the Institutional Review Board of the Hadassah Medical Organization.
Upon receipt of the cannabis license, participants were educated on proper cannabis use and received a prescription for the study medication, which was dispensed at preapproved distribution points by a certified provider. The initial recommended cannabis dose was 20 g/mo, which could be obtained as smoked cannabis (patients could either roll the cigarette themselves or obtain prefilled 1 g cannabis cigarettes) or the same monthly amount dispensed in baked cookies, or as an olive oil extract (drops).
The patients were instructed to titrate the cannabis dose starting with 1 cigarette puff (or 1 drop of the cannabis oil) a day, and increase by increments of 1 puff/drop per dose, to a frequency of up to 3 times a day until satisfactory pain relief was achieved, or side effects appeared. Cannabis was to be consumed at the home address only. Participants were instructed to refrain from driving for at least 6 hours after consuming cannabis or longer if they felt disoriented or drowsy.
If no adequate pain relief was achieved, and the patient did not report adverse effects with the monthly dose of 20 g, the dose could be further increased on the basis of the physician's judgment and subsequent approval by the Ministry of Health.
The Israeli Ministry of Health has standard regulations on approved strains and cultivating procedures for licensed cannabis dispensaries. At the time of the study, there were no Good Manufacturing Practices in place for medicinal cannabis; however, the Ministry of Health performs occasional measurements of quality and THC/CBD levels to ascertain that the products meet minimum and maximum THC/CBD concentrations. The THC concentration in the smoked product is 6% to 14% (11% to 19% in oral formulations, eg, cookies), and the CBD concentration is 0.2% to 3.8% (0.5% to 5.5% in oral formulation) (data source-Israeli Ministry of Health).
Cannabis treatment was added to the existing analgesic regimen. The study did not include a formal requirement to discontinue other analgesics; however, all participants were encouraged to attempt gradual dose reduction and possible discontinuation of other analgesics, particularly chronic opioids, due to potential long-term concerns of endocrinopathy 26 and cognitive dysfunction. 27 The efficacy of cannabis on pain and pain-related quality of life (QoL) was assessed by administering the S-TOPS (Treatment Outcomes in Pain Survey-Short Form) questionnaire, 28 the sleep problem index (SPI) subscale of the MOS sleep measure, 29 and the Brief Pain Inventory (BPI) 30, 31 before the treatment, and approximately at the 6month clinic follow-up.
The primary outcome was pain reduction (change from baseline) after 6 months as assessed by the Pain Symptom scale of the S-TOPS instrument in the intentto-treat (ITT) population. Secondary outcomes included a change from baseline in the following: (1) physical disability, family and social disability, role-emotional disability, and patient satisfaction with outcomes scales of the S-TOPS; (2) SPI; (3) pain severity and pain interference scales of the BPI; (4) opioid consumption. Outcome analyses were also performed for the per-protocol (PP) population.
Patient-reported side effects were collected at each clinic visit and at the time of follow-up questionnaire completion. Side effects were considered serious if they were life-threatening, resulted in hospitalization or emergency department visits, or required medical intervention for resolution.
Statistical Analyses
A change from baseline of primary and secondary outcomes was assessed by the paired t test for normally distributed data and by the Wilcoxon signed rank test for non-normally distributed data. The normality of data distribution was assessed by the Shapiro-Wilk test. The baseline observation carried forward imputation method was used for ITT analysis for both primary and secondary outcomes. PP analysis was performed for completers to assess the robustness of the findings. These methods were also used for subgroup analyses. Although the baseline observation carried forward and PP have their limitations, 32 our study design prevented us from constructing a more comprehensive imputation algorithm such as a mixedeffect regression model, as the lack of multiple follow-ups did not allow us to determine patterns of missing data reliably. Linear regression analysis was performed to test the possible association between improved pain and deterioration in physical function. A priori sample size calculation was not performed, as we had no prior data on what might be the expected effect size of cannabis treatment on our primary outcome measure. The goal was to enroll a sample larger than 150 participants to enable the robust assessment of its effect.
Differences were considered significant at P < 0.05 level. Normally distributed data are presented as mean, categorical data are presented as median, with either SD or 95% confidence interval (CI) as appropriate. Statistical analyses were performed with SigmaPlot 12.5 (Systat Software Inc.).
RESULTS

Participant Flow and Baseline Characteristics
Overall, 308 patients have been considered for cannabis treatment (patient disposition CONSORT chart in Fig. 1 ). The treatment for 34 patients was not approved by the Ministry of Health (diagnoses: low back pain, n = 9; fibromyalgia, n = 8; radicular low back pain, n = 5; widespread myofascial pain, n = 5; peripheral neuropathic pain, n = 2; central neuropathic pain, n = 1; persistent postsurgical pain, n = 1; postamputation pain, n = 1; widespread pain after traumatic brain injury, n = 1; and complex regional pain syndrome, n = 1). Forty-nine participants had either missing baseline S-TOPS data or completed the first questionnaire after beginning the cannabis treatment and were excluded from analysis. Nineteen terminal cancer patients (11 of whom had metastatic cancer pain) died before or soon after treatment initiation; none of the deaths was judged to be related to the study drug. Eleven participants discontinued the treatment early because of side effects, and 4 participants discontinued due to ineffectiveness. Fifteen participants were lost to followup or have been self-discharged to a different pain clinic, and therefore had no follow-up data available. ITT analysis was performed on all 206 participants who provided baseline data. A total of 176 participants completed the study and were included in the PP analysis.
In the ITT population, the average participant age was 51.2 (15.4) years, and 62.0% of the participants were male (127 male, 79 female), and the most frequent diagnoses were musculoskeletal widespread pain (n = 62, 30.1%), peripheral neuropathic pain (n = 49, 23.8%), and radicular low back pain (n = 39, 18.9%). The majority of the participants (n = 192, 93.2%) had chronic noncancer pain, whereas 14 (6.8%) participants had cancer pain. Additional baseline pain characteristics are presented in Table 1 , and the distribution of pain conditions are shown in Table 2 . The mean (SD) follow-up to completion of outcome assessment (S-TOPS and BPI) was 210 (96.6) days. Patient disposition in the PP population was not significantly different. At the follow-up, 136 participants received cannabis cigarettes, 8 participants received a combination of cigarettes and drops, 17 participants received only drops, 9 participants received only cookies, and 6 received a combination of cookies and drops. The mean (SD) monthly prescribed amount of cannabis at follow-up (in any route of administration) was 43.2 (17.9) g. Before cannabis treatment, 73 of the 176 participants in the PP population received analgesic treatment with strong opioids (morphine, oxycodone, fentanyl, hydromorphone, buprenorphine, and methadone). An additional 10 participants received tramadol and 5 participants received both tramadol and a strong opioid. The detailed use of strong opioids is presented in Table 3 . The median daily dose among opioid users (in daily oral morphine sulfate equivalents) was 60.0 mg (95% CI, 45.0-90.0). Conversion rates from the daily morphine sulfate dose (mg) were as follows: 30 to 20 mg/d oral oxycodone; 30 to 10 mcg/h for transdermal 
The Primary Outcome
The S-TOPS pain symptom score improved from 83.3 (95% CI, 79.2-87.5) to 75.0 (95% CI, 70.8-79.2) (P < 0.001). Overall, the pain symptom score improved in 65.9% of the participants, did not change from baseline in 8.0%, and deteriorated in 26.1% of the participants. In the PP analysis, the improvement in the pain symptom score was similar-from 83.3 (95% CI, 79.2-87.5) to 75.0 (95% CI, 70.8-79.2) (P < 0.001).
Secondary Outcomes
S-TOPS family-social disability, role-emotional disability, satisfaction with outcomes, and SPI all improved from baseline (P < 0.001) (Fig. 2) . BPI subscales of pain severity and pain interference were also significantly improved from baseline (all P < 0.01) (Fig. 3) . The change in physical disability-lower body scale was not significant in the ITT population, but significant in the PP population: from 75.0 (95% CI, 75.0-83.3) to 75.0 (95% CI, 66.7-75.0) (P < 0.001). The physical disability-upper body scale of S-TOPS did not change from baseline to follow-up (P = 0.48).
Of 73 participants on opioid therapy at baseline, 32 discontinued opioid treatment at follow-up. This is a 44% reduction from baseline in the percentage of participants receiving opioid treatment (41 vs. 73, P < 0.001). Two participants continued receiving tramadol, and none received both tramadol and strong opioids at follow-up. The median oral morphine equivalent dose among the participants still receiving opioids at follow-up decreased from 60.0 mg (95% CI, 45.0-90.0) to 45 mg (95% CI, 30.0-90.0); however, this reduction did not reach statistical significance (P = 0.19, Mann-Whitney test).
In a subgroup analysis, there were no differences in the primary outcome between neuropathic (peripheral or central neuropathic pain, n = 59) and non-neuropathic (all nociceptive and mixed pain diagnoses, n = 147) pain, or between male (n = 127) and female (n = 79) patients. We also tested the association between the change in the S-TOPS pain symptom score and the change in the S-TOPS physical disability scale to confirm that the improved pain did not come at the expense of increased functional impairment. Linear regression analysis showed that the improvement in pain was significantly associated with improvement in physical function (r = 0.35. P < 0.001).
Adverse Effects
Nine participants discontinued treatment due to mild to moderate adverse effects (AEs): primarily sedation, heaviness, nervousness, and difficulty to concentrate. Two additional participants discontinued treatment due to serious side effects: 1 participant because of elevated liver transaminases, and 1 elderly participant was admitted to the emergency room in a confusional state and was discharged after 4 days of hospitalization. Both participants were receiving cannabis drops at the time the AEs were recorded.
DISCUSSION
In this prospective open-label study with a mean follow-up of 7 months, patients with chronic pain showed improvement from baseline in pain and pain-related QoL outcomes after treatment with medicinal cannabis. Results in this mixed group of nociceptive and neuropathic pain patients are consistent with previous smaller, short-term studies, [20] [21] [22] [37] [38] [39] [40] [41] and a recent large long-term study, 42 demonstrating effectiveness of smoked cannabis in chronic pain.
A significant percentage of the participants discontinued opioid therapy during the study. This type of reduction in opioid requirements with cannabinoid therapy is consistent with previous reports, 43, 44 and supported by preclinical findings on the synergistic analgesic efficacy of opioids and cannabinoids. 45, 46 Opioid use for chronic pain increases the risk of endocrinopathy, bowel dysfunction, cognitive decline, hospitalization, and death from overdose, and is also associated with increased costs and comorbidities. [47] [48] [49] With a recent study reporting that introducing medicinal cannabis laws resulted in decreased state-level opioid overdose mortality rates, 50 this is an important area for further research.
Short-term AEs of acute cannabis exposure or cannabis toxicity are well-documented; these affect a variety of systems and include nausea, dizziness, headache, increased heart rate, reduced auditory/verbal and visual/spatial memory recall and recognition, and poorer attention and reaction times. 22, 51 Long-term effects of cannabis, however, especially in the setting of chronic pain management, are less documented. A systematic review of cannabis treatment under a variety of conditions (eg, pain, glaucoma, MS, nausea) reported no difference in serious side effects or death between cannabis and controlled groups, but an increased risk of nonserious side effects, especially respiratory, neurological, gastrointestinal, psychiatric, and eye disorders, was found. 52 The rate of cannabis discontinuation due to side effects in our study was low (11/206 participants, 5.3%), and almost identical to the recent prospective COMPASS study (10/215 participants discontinued due to side effects). 42 Numerous studies have reported an association between illegal use of cannabis and cardiovascular and cerebrovascular risks by detecting cannabinoids in blood or urine screens after myocardial infarction or stroke, but it is very challenging to establish causality, as many of these participants have had numerous risk factors for these conditions including comorbidities and the use of tobacco, alcohol, and other illicit drugs. 53 In addition, some but not all studies suggest that acute consumption of cannabinoids has also been linked with an increased likelihood of being involved in motor vehicle accidents 54 ; however, clear guidance regarding abstinence from driving while under cannabinoid treatment has not been established, especially in the case of lawfully prescribed, chronic treatment. 55 On the basis of some experimental data, the suggestion is not to drive for at least 3 to 4 hours after cannabis consumption. 56, 57 Our recommendation to abstain from driving for 6 hours, although more conservative, is based on the large interpatient variability in THC pharmacokinetics. 58 Because of the increasing use of medicinal cannabis in many countries worldwide, recommendations have been published recently, 59, 60 with regard to patient selection, monitoring, dosing regimen selection, and driving; however, these should be regarded as preliminary guidelines until more consistent data are available.
Hepatic impairment is rarely associated with cannabis use, but abnormal liver transaminase levels have been reported, 61 and it is plausible to assume that an increase in liver transaminase levels in one of the study participants was treatment-related. Although psychiatric AEs such as acute psychosis have been reported with cannabis use, no such effects occurred in our study. One elderly patient (83 y old) was hospitalized in a confusional state, and this was considered by the caregivers to be associated with the cannabis treatment. We did not have an upper age limitation for inclusion in our study, but perhaps the use of cannabis in the elderly population warrants greater caution. Both serious AEs that caused treatment discontinuation occurred while the participants took the cannabis olive oil extract at the monthly dose of 20 mg. A large variability in the rate and the extent of absorption with oral cannabinoids has been reported, 62,63 but we do not know whether FIGURE 3 . Changes in the Brief Pain Inventory (BPI) pain severity and pain interference from baseline (gray) to follow-up (dotted white), in the ITT population. The BPI pain severity score changed from median 7.50 (95% confidence interval [CI], 6.75-7.75) to 6.25 (95% CI, 5.75-6.75), and the pain interference score from median 8.14 (95% CI, 7.28-8.43) to 6.71 (95% CI, 6.14-7.14) (***P < 0.001).
the mode of administration played a critical role in these participants.
One of the possible reasons for the infrequency of psychiatric AEs in our study could be the rigorous patient selection process and comprehensive patient education. We set strict criteria and excluded participants with a background or a family history of schizophrenia, psychosis, and similar psychiatric disorders. In addition, the participants underwent a detailed assessment of potential for drug abuse and treatment noncompliance by a psychologist and a clinical pharmacist, respectively.
The main limitations to the clinical use of cannabis for chronic pain have been the lack of long-term prospective studies on effectiveness, the concern of cognitive and psychiatric AEs, 64 and legal issues associated with cannabis use. Brief interventions in crossover controlled studies or long-term follow-ups in small groups of patients are typically not sufficient to address these limitations. Our study addresses the changes in pain and pain-related QoL outcomes over 7 months of treatment, and demonstrates a relative low incidence of AEs in a carefully selected group of participants. Overall, the rate of serious AEs and discontinuation due to AEs was low in our study, and this is consistent with findings in a systematic review of the literature on cannabinoid treatment of chronic pain, where among 18 studies involving 766 participants, no serious AEs were reported, and most of the reported AEs were tolerable and did not lead to treatment discontinuation. 18 The dosing of cannabinoids for pain has been another important matter of debate; there is a wide variability in various reported and recommended doses for medicinal cannabis for pain, ranging from 12 to 48 g/mo. 60, 65 This perhaps reflects the wide interindividual variability in the pharmacological response to cannabis and the lack of a clear dose-response relationship, 51 necessitating an individually adjusted dose titration. The variability in the active cannabinoid concentration in the final product may further contribute to an inconsistency in different recommendations. Although the cultivation process is standardized by the Israeli Ministry of Health, including the periodic measurement of THC and CBD concentrations, it is not a pharmaceutical grade product, and the up to 3-fold variability in the THC concentration among the various dosage forms (6% minimal concentration in the smoked and 19% maximum concentration in the oral dosage forms) could have affected our results.
The physical disability-upper body and physical disability-lower body subscales of the S-TOPS questionnaire did not change significantly from baseline in our study. This result on upper body disability is not unexpected, given the low disability scores at baseline, but together these data may suggest that cannabis treatment preferentially affects the perception of pain and its emotional and social implications, rather than objectively determined physical disability.
Strengths and Limitations of the Study
The main limitation of this study was the lack of a control group. In treating pain, the placebo effect can be substantial 66 ; therefore, our ability to draw conclusions about the true pharmacological efficacy of cannabis in this study is limited. An additional limitation of this type of cohort study is a lack of frequent periodic assessment of all AEs, which resulted in capturing primarily serious AEs and those that led to treatment discontinuation. In addition, we have systematically assessed baseline pharmacotherapy and subsequent dose changes with opioids only, but our methodology allowed neither the determination of the causality between cannabis treatment and opioid consumption nor testing the association between cannabis treatment and changes in the consumption of nonopioid analgesics. In this cohort, 63% of the study population was male, which may misrepresent the general chronic pain population. Typically, chronic pain prevalence is 20% to 30% higher in women, 2 whereas painful conditions such as fibromyalgia may be 2 to 13 times more prevalent in women, depending on the diagnostic criteria. 67 However, the outcomes were not different for men and women, when analyzed separately.
Despite these limitations, performing a randomized, controlled trial of a similar size and duration, considering the unconventional route of cannabis delivery, is associated with immense challenges. Our results demonstrate not only a symptomatic long-term improvement in pain scores, but rather a robust functional improvement on various QoL domains including sleep, and substantial improvement in satisfaction with treatment outcomes. The significant decrease in the percentage of patients treated with opioids suggests an objective improvement after cannabis treatment.
In summary, this long-term prospective cohort suggests that cannabis treatment in a mixed group of patients with treatment-resistant chronic pain may result in improved pain, sleep, and QoL outcomes, as well as reduced opioid use. There are limitations to this open-label study that should be considered carefully before extrapolating the study results to the general population: these are primarily its uncontrolled design and careful patient selection for low drug abuse, psychiatric illness, and nonadherence risks.
